Dechra Pharmaceuticals PLC — AGM Information 2017

Oct 20, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2365U

Dechra Pharmaceuticals PLC

20 October 2017

Date: 20 October 2017

Dechra® Pharmaceuticals PLC

Results of Annual General Meeting (AGM)

AGM Meeting Date: 1pm on 20 October 2017

Issued Share Capital at meeting date: 93,415,750

Number of shareholders in attendance: 12

All resolutions were passed on a show of hands.

Details of the proxy voting instructions lodged prior to the AGM are set out below:

Resolution (No. as noted on proxy form)	Total For (1)		Total Against		Withheld (2)
	No. of votes	% of vote	No. of votes	% of vote	No. of votes
Resolution 1: To receive the accounts, the Strategic Report, the Directors' Report and the Auditor's Report	69,787,352	94.83	3,801,367	5.17	176,986
Resolution 2: To receive and approve the Directors' Remuneration Report	66,111,495	94.18	4,086,647	5.82	3,567,713
Resolution 3: To receive and approve the Directors' Remuneration Policy	72,932,631	98.88	823,955	1.12	8,619
Resolution 4: To declare a final dividend	73,764,546	100	0	0.00	659
Resolution 5: To elect Richard Cotton	72,195,608	97.87	1,568,938	2.13	659
Resolution 6: To elect Lawson Macartney	73,401,877	99.51	361,469	0.49	1,859
Resolution 7: To re-elect Tony Rice	66,992,715	92.48	5,448,270	7.52	1,324,220
Resolution 8: To re-elect Ian Page	72,285,663	98.00	1,478,883	2.00	659
Resolution 9: To re-elect Anthony Griffin	72,279,341	97.99	1,485,205	2.01	659
Resolution 10: To re-elect Julian Heslop	73,500,858	99.64	263,688	0.36	659
Resolution 11: To re-elect Ishbel Macpherson	73,144,501	99.16	620,045	0.84	659
Resolution 12: To reappoint PricewaterhouseCoopers as external auditor of the Company	73,756,778	99.99	7,318	0.01	1,109
Resolution 13: To authorise the Audit Committee to determine the remuneration of the external auditor	73,763,069	100	1,027	0.00	1,109
Resolution 14: To authorise the Directors to allot shares to specific limits	69,568,791	94.32	4,191,805	5.68	4,609
Resolution 15: To disapply the pre-emption rights	72,858,327	98.78	903,219	1.22	3,659
Resolution 16: To disapply additional pre-emption rights	67,395,228	91.37	6,366,318	8.63	3,659
Resolution 17: To authorise the Company to purchase its own shares	72,978,224	99.07	685,466	0.93	101,515
Resolution 18: To call general meetings (other than an AGM) on not less than 14 clear days' notice	71,828,591	97.38	1,935,505	2.62	1,109
Resolution 19: (a)  To approve the rules of the LTIP 2017; and (b)  To authorise the Directors to adopt further schemes based on the LTIP 2017	70,433,043	95.49	3,328,963	4.51	3,199

Notes

1.   Includes discretionary votes.

2.   A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "For" and "Against" a resolution.

3.   Resolutions 1 to 14 and Resolution 19 were ordinary resolutions, requiring more than 50% of shareholder votes to be "for" the resolutions.

4.   Resolutions 15 to 18 were special resolutions, requiring more than 75% of shareholder votes to be "for" the resolutions.

5.   Votes tendered in respect of 73,765,205 shares representing 78.96% of the issued share capital.

In accordance with Listing Rule 9.6.2R, a copy of the resolutions passed as special business at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.

For further information

Melanie Hall, Company Secretary                           

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information, please visit: www.dechra.com.

Trademarks

Trademarks appear throughout this document in italics.  Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGFMMZGFGDGNZM